Sector Pharmaceuticals & Biotech. - Latest news, views and updates

SECTOR | 16 Jul 2025

Senate votes to move ahead with Trump's request for $9 bn in spending cuts

Business Standard

Senate Republicans on Tuesday advanced President Donald Trump's request to cancel some USD 9 billion in previously approved spending, overcoming concerns from some lawmakers about what the rescissions could mean for impoverished people around the globe and for public radio and television stations in their home states. The Senate vote was 50-50, with Vice President JD Vance breaking the tie. A final vote in the Senate could occur as early as Wednesday. The bill would then return to the House for another vote before it would go to Trump's desk for his signature before a Friday deadline. Republicans winnowed down the president's request by taking out his proposed USD 400 million cut to a programme known as PEPFAR. That change increased the prospects for the bill's passage. The politically popular programme is credited with saving millions of lives since its creation under then-President George W. Bush to combat HIV/AIDS. The president is also looking to claw back money for foreign aid

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 15 Jul 2025

WHO approves injectable HIV drug lenacapavir for high-risk communities

Business Standard

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk groups, as global HIV prevention efforts face funding setbacks

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Aurobindo Pharma to manufacture, supply long acting HIV treatment drug

Business Standard | 15 Jul 2025 1 more

Pharmaceuticals & Biotech.

SECTOR | 14 Jul 2025

Gland Pharma shares rise on GMP nod for Telangana manufacturing unit

Business Standard

Gland Pharma shares rose 2 per cent after it received a GMP certification from the Danish Medicines Agency for its Telangana plant

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 13 Jul 2025

India's dengue vaccine Phase-3 trial enrolment to be completed by Oct: ICMR

Business Standard

Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed dengue vaccine, DengiAll, is likely to be completed by October across 20 centres in India, according to ICMR scientists. So far, 8,000 participants in various centres at Pune, Chennai, Kolkata, Delhi and Bhubaneswar among others have received either the vaccine or a placebo as part of the trial sponsored by the Indian Council of Medical Research (ICMR) and Panacea Biotec. The trial is co-led by ICMR-National Institute of Translational Virology and AIDS research in Pune, National Institute of Epidemiology (NIE), Chennai and National Institute of Virology, Pune. Currently, there is no antiviral treatment or licensed vaccine against dengue in India. The results of the Phase-1/2 trial has shown no safety concerns for the one-shot vaccine, NIE Director Dr Manoj Murhekar said. "The participants enrolled in the Phase- III trial will be followed up for two-years. This

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

US aid cuts halt HIV vaccine research in South Africa, with global impact

Business Line | 13 Jul 2025 1 more

Pharmaceuticals & Biotech.

SECTOR | 13 Jul 2025

Electronics, pharma sectors corner 70% of PLI disbursements in FY25

Business Standard

Large-scale electronics manufacturing and pharmaceuticals cornered about 70 per cent of the total fiscal incentive disbursements in 2024-25 under the production-linked incentive (PLI) schemes, according to government data. The scheme was introduced in 2021 to support domestic manufacturing across 14 sectors with an outlay of Rs 1.97 lakh crore. In 2024-25, the government has disbursed a total of Rs 10,114 crore. PLI firms in the electronics sector received Rs 5,732 crore, while pharmaceutical drugs received Rs 2,328 crore, the data showed. In 2023-24, the disbursals stood at Rs 9,721 crore. The figures highlight the country's growing strength in these segments amid efforts to boost manufacturing and value-added exports. Besides these two, the other sectors that received these incentives in the last fiscal include bulk drugs (Rs 22 crore), Medical Devices (Rs 77 crore), Telecom (Rs 840 crore), Food Processing (Rs 448 crore), White Goods (Rs 210 crore), Automobiles (Rs 322 crore), .

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 10 Jul 2025

UNAIDS Calls For Nations To Fill The Gap As Trump Pulls Funding

NDTV Profit

Even before the disruption, 9.2 million people who have HIV were still not able to get access to life-saving treatment in 2024, according to the Global Aids Update.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 09 Jul 2025

Stocks To Watch Today: JSW Steel, Tata Steel, Zee, NTPC, Pharma Companies

NDTV Profit

NTPC and Puravankara are also some of the stocks to watch on Wednesday.

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 09 Jul 2025

Q1FY26 Earnings Preview - Pharma and Healthcare

Pharmaceuticals & Biotech.

Axis Direct

Q1FY26 Earnings Preview - Pharma & Healthcare

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 08 Jul 2025

Q1FY26E Pharmaceuticals Sector Preview

Pharmaceuticals & Biotech.

Deven Choksey

As per Pharma rack data, during Apr’25, the Indian pharmaceutical market (IPM) grew by 7.8% YoY, led by improved price realization (+5.1% YoY), modest new launches (+2.3% YoY), and muted volume growth (+0.4% YoY).

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.

Pharmaceuticals & Biotech.

SECTOR | 07 Jul 2025

Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy

Business Standard

Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for Vevzuo and Evfraxy, biosimilars of Denosumab used in the treatment of bone-related diseases. Vevzuo is authorised for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, Biocon said in a regulatory filing. It is also authorised for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. On the other hand, Evfraxy is authorised for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, the company said. In postmenopausal women, this significantly reduces the risk of vertebral, non-vertebral, and hip fractures, it...

Axis Direct released a Sector Update report for Pharmaceuticals & Biotech. on 09 Jul, 2025.